Bioatla, INC Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ
OPOKA Investment Fund Co has reduced its beneficial ownership in BioAtla, Inc. to 4.8% of common stock, indicating a passive investment stance.
NASDAQ
Acorn Bioventures, L.P., Acorn Bioventures 2, L.P., and their affiliates, including Anders Hove, have disclosed a combined beneficial ownership of 8.3% of BioAtla, Inc.'s common stock as a passive investment.
NASDAQ
Highbridge Capital Management, LLC has filed an amended Schedule 13G, disclosing a 7.7% beneficial ownership stake in BioAtla, Inc., primarily through warrants.
NASDAQ
Opoka Investment Fund Co. has disclosed a 6.1% passive ownership stake in BioAtla, Inc., holding 3,547,787 common shares.
NASDAQ
Highbridge Capital Management, LLC has reported a 9.9% beneficial ownership stake in BioAtla, Inc., including shares issuable upon warrant exercise, as of December 31, 2024.
NASDAQ
BioAtla, Inc.'s Co-founder, Chairman, and CEO, Jay M. Short, has filed an amended Schedule 13G, disclosing a beneficial ownership of 6.6% of the company's common stock as of December 31, 2024.
NASDAQ
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed an amended Schedule 13G, reporting a passive beneficial ownership of 1.9% in BioAtla, Inc.'s common stock as of December 31, 2024.